Companies · Biotechnology

PolyPid Ltd.

PETACH TIKVA · Biotechnology

Diligence memoA one-page analyst read on PolyPid Ltd. — recommendation, valuation, rhythm, risks.
$125.4M
Total raised · real
6
Rounds
1.8×
Latest step-up
Top 8%
Sector rank · raised
Series B
Latest stage · inferred · Mon Jun 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

PolyPid Ltd. looks over-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.63× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Active
  • Last raise 13 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

PolyPid Ltd. is one of 4293 Biotechnology companies tracked from PETACH TIKVA. By capital raised it ranks among the largest (ahead of 93% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
20
Investors (latest)
2025-06-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries A · 2016-02-04 Raised $8.1M (real) Modeled valuation $294M (est)$8.1M$294MSeries A2016Series B · 2019-06-28 Raised $27M (real) Modeled valuation $1.1B (est)$27M$1.1BSeries B2019Series B · 2024-01-09 Raised $35M (real) Modeled valuation $306M (est)$35M$306MSeries B2024Series B · 2024-08-06 Raised $14M (real) Modeled valuation $97M (est)$14M$97MSeries B2024Series B · 2024-12-26 Raised $15M (real) Modeled valuation $84M (est)$15M$84MSeries B2024Series B · 2025-06-16 Raised $27M (real) Modeled valuation $126M (est)$27M$126MSeries B2025+$27M+$35M+$14M+$15M+$27MCumulative $125M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$8.1M · 2016
Series B$26.9M · 2019
Series B extension$35.0M · 2024
Series B extension$14.2M · 2024
Series B extension$14.5M · 2024
Series B extension$26.7M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$126.2M
Base estimate est.
$53.4M
Conservative case
$188.1M
Upside case
$148.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $294.1M · 2016-02-042016Series B · modeled $1.1B · 2019-06-28Series B · modeled $306.4M · 2024-01-09Series B · modeled $97.1M · 2024-08-06Series B · modeled $83.9M · 2024-12-26Series B · modeled $126.2M · 2025-06-162025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
1.0 yr
Elapsed time used
1.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
22 mo
Avg between rounds
$13.4M/yr
Capital velocity
10.4 yr
On record since
2016
First round
6
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 17× above median
This company$125.4M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 1.5× above median
This company$26.7M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 2.0× above median
This company$126.2M
Sector median$64.2M

Raised more than 93% of sector peers (real $). Modeled value above 63% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #15 of 94.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0M$1.0BCapital raised (log)MarvelBiome, Inc. · Series B Raised $54.9M · modeled $163.2M (est)Iantrek, Inc. · Series B Raised $58.2M · modeled $152.4M (est)Dualitas Therapeutics, Inc. · Series B Raised $32.6M · modeled $150.4M (est)Antares Therapeutics, Inc. · Series B Raised $70.0M · modeled $149.7M (est)OrthoBio Therapeutics, Inc. · Series B Raised $31.4M · modeled $147.5M (est)Medcura, Inc. · Series B Raised $40.9M · modeled $145.0M (est)Neurolutions Inc · Series B Raised $26.5M · modeled $144.9M (est)Renasant Bio, Inc. · Series B Raised $55.5M · modeled $144.0M (est)Caldera Therapeutics, Inc. · Series B Raised $37.5M · modeled $139.2M (est)VitriVax, Inc. · Series B Raised $29.4M · modeled $136.9M (est)DiaMedica Therapeutics Inc. · Series B Raised $110.4M · modeled $136.3M (est)OmniAb, Inc. · Series B Raised $30.0M · modeled $130.5M (est)PolyPid Ltd. (this company) Raised $125.4M · modeled $126.2M (est)PolyPid Ltd.
CompanyStageRaised · realValue · estvs peer med.
MarvelBiome, Inc.Series B$54.9M$163.2M2.11×
Iantrek, Inc.Series B$58.2M$152.4M1.97×
Dualitas Therapeutics, Inc.Series B$32.6M$150.4M1.94×
Antares Therapeutics, Inc.Series B$70.0M$149.7M1.93×
OrthoBio Therapeutics, Inc.Series B$31.4M$147.5M1.90×
Medcura, Inc.Series B$40.9M$145.0M1.87×
Neurolutions IncSeries B$26.5M$144.9M1.87×
Renasant Bio, Inc.Series B$55.5M$144.0M1.86×
Caldera Therapeutics, Inc.Series B$37.5M$139.2M1.80×
VitriVax, Inc.Series B$29.4M$136.9M1.77×
DiaMedica Therapeutics Inc.Series B$110.4M$136.3M1.76×
OmniAb, Inc.Series B$30.0M$130.5M1.68×
PolyPid Ltd. this companySeries B$125.4M$126.2M1.63×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$8.1M2016-02-04$37.0M$294.1M85%
Series B$26.9M2019-06-28$149.2M$1.1B90%
Series B$35.0M2024-01-09$194.5M$306.4M90%
Series B$14.2M2024-08-06$78.9M$97.1M90%
Series B$14.5M2024-12-26$80.6M$83.9M90%
Series B$26.7M2025-06-16$148.3M$126.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$8.1M2016-02-04
    • First recorded raise — entered as Series A.
    • 8 investors on this round.
  2. Series B$26.9M2019-06-28
    • Raised again after 41 mo — slower than the ~14 mo sector norm.
    • Round 3.3× larger than the prior — scaling up.
    • 361 investors on this round.
  3. Series B$35.0M2024-01-09
    • Raised again after 54 mo — slower than the ~14 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 20 investors on this round.
  4. Series B$14.2M2024-08-06
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 17 investors on this round.
  5. Series B$14.5M2024-12-26
    • Came back fast: 5 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 12 investors on this round.
  6. Series B$26.7M2025-06-16
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 1.8× larger than the prior — scaling up.
    • 20 investors on this round.
Intelligence
2027 ~Q2
Modeled next raise · ~22mo cadence
$49.1M
Modeled next size est.range $31.9M$78.6M
1.8×
Last step-up
$13.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert B. Stein4 other2024-01
Yechezkel Barenholz2 other2024-01
Itzhak Krinsky1 other2024-01
Nir Dror1 other2024-01
Amir Weisberg2016-02
Anat Tsour Segal2019-06
Chaim Czaczkes Hurvitz2019-06
Dalit Czaczkes Hazan2019-06
Dalit Hazan2024-01
Dikla Czaczkes Akselbrad2016-02
Eitan Kyiet2016-02
Eli Czaczkes Frydman2019-06
Gerry Tsour Rubens2019-06
Itzhak Tsour Krinsky2019-06
Jacob Czaczkes Harel2019-06
Jacob Harel2024-01
Jonny Missulawin2024-01
Noam Czaczkes Emanuel2019-06
Noam Emanuel2016-02
Nurit Tweezer-Zaks2024-01
Ori Warshavsky2024-01
Shaul Czaczkes Mukhtar2019-06
Shaun Marcus2016-02
Yechezkel Czaczkes Barenholz2019-06
Registry & provenance

PolyPid Ltd. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1611842
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Tarveda Therapeutics, Inc.BiotechnologySeries B$127.4M$141.9Msame sector · same stage
Alung Technologies IncBiotechnologySeries B$130.6M$126.8Msame sector · same stage
DiaMedica Therapeutics Inc.BiotechnologySeries B$110.4M$136.3Msame sector · same stage
ReAlta Life Sciences, Inc.BiotechnologySeries B$108.3M$146.1Msame sector · same stage
Agenus IncBiotechnologySeries C$211.2M$1.2Bnetwork1 shared operator · same sector
Vaxinnate CorpBiotechnologySeries B$92.6M$128.9Msame sector · same stage
EvolveImmune Therapeutics Holding Company, LLCBiotechnologySeries B$85.8M$124.9Msame sector · same stage
Instylla, Inc.BiotechnologySeries B$85.5M$100.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Polybiomics Inc.BiotechnologySeed$111.0M86%
Respiderm CorpBiotechnologyPre-Seed$20.7M85%
pHLIP, Inc.BiotechnologySeries A$159.5M84%
PharmaTher Holdings Ltd.BiotechnologySeries A$156.6M83%
Quadric BioMed, LLCBiotechnologyPre-Seed$6.4M83%
P2 Science, Inc.BiotechnologySeries B$619.5M83%
Opus Genetics, Inc.BiotechnologySeries B$161.0M83%
Opus Genetics Inc.BiotechnologySeries A$39.7M83%
Frequently asked
How much funding has PolyPid Ltd. raised?
PolyPid Ltd. has raised approximately $125.4M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is PolyPid Ltd.'s estimated valuation?
Provath's modeled valuation for PolyPid Ltd. is approximately $126.2M (modeled range $53.4M–$188.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is PolyPid Ltd. at?
PolyPid Ltd.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Mon Jun 16.
What does PolyPid Ltd. do and where is it based?
PolyPid Ltd. operates in the Biotechnology sector, based in PETACH TIKVA.
Explore related

See where PolyPid Ltd. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at PolyPid Ltd., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.